Price T Rowe Associates Inc. MD Lowers Stock Position in West Pharmaceutical Services, Inc. (NYSE:WST)

Price T Rowe Associates Inc. MD trimmed its stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 12.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,032,890 shares of the medical instruments supplier’s stock after selling 294,504 shares during the period. Price T Rowe Associates Inc. MD owned 2.79% of West Pharmaceutical Services worth $804,436,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Evoke Wealth LLC purchased a new position in West Pharmaceutical Services during the fourth quarter valued at $7,770,000. Sumitomo Mitsui Trust Holdings Inc. lifted its holdings in West Pharmaceutical Services by 1.5% during the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 191,469 shares of the medical instruments supplier’s stock valued at $75,766,000 after purchasing an additional 2,759 shares in the last quarter. International Assets Investment Management LLC lifted its holdings in West Pharmaceutical Services by 13,230.0% during the fourth quarter. International Assets Investment Management LLC now owns 18,662 shares of the medical instruments supplier’s stock valued at $6,571,000 after purchasing an additional 18,522 shares in the last quarter. Vanguard Group Inc. lifted its holdings in West Pharmaceutical Services by 1.2% during the fourth quarter. Vanguard Group Inc. now owns 9,002,632 shares of the medical instruments supplier’s stock valued at $3,170,007,000 after purchasing an additional 104,740 shares in the last quarter. Finally, Mizuho Markets Americas LLC lifted its holdings in West Pharmaceutical Services by 142.3% during the first quarter. Mizuho Markets Americas LLC now owns 29,628 shares of the medical instruments supplier’s stock valued at $11,724,000 after purchasing an additional 17,399 shares in the last quarter. 93.90% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at West Pharmaceutical Services

In other news, SVP Silji Abraham sold 1,800 shares of the firm’s stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $330.78, for a total value of $595,404.00. Following the transaction, the senior vice president now directly owns 2,860 shares of the company’s stock, valued at $946,030.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, CEO Eric Mark Green sold 66,000 shares of the firm’s stock in a transaction dated Tuesday, May 7th. The shares were sold at an average price of $366.65, for a total transaction of $24,198,900.00. Following the completion of the sale, the chief executive officer now directly owns 152,908 shares in the company, valued at $56,063,718.20. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Silji Abraham sold 1,800 shares of the firm’s stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $330.78, for a total transaction of $595,404.00. Following the sale, the senior vice president now owns 2,860 shares of the company’s stock, valued at $946,030.80. The disclosure for this sale can be found here. Insiders own 0.53% of the company’s stock.

West Pharmaceutical Services Price Performance

WST traded up $7.60 during midday trading on Friday, hitting $284.76. 1,190,418 shares of the company traded hands, compared to its average volume of 675,234. The company has a current ratio of 2.61, a quick ratio of 1.95 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $20.74 billion, a price-to-earnings ratio of 37.57, a PEG ratio of 6.03 and a beta of 1.00. West Pharmaceutical Services, Inc. has a 52-week low of $265.00 and a 52-week high of $415.73. The business has a 50 day simple moving average of $324.09 and a two-hundred day simple moving average of $355.79.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings results on Thursday, July 25th. The medical instruments supplier reported $1.52 earnings per share for the quarter, missing the consensus estimate of $1.74 by ($0.22). The business had revenue of $702.10 million during the quarter, compared to analysts’ expectations of $729.36 million. West Pharmaceutical Services had a return on equity of 18.78% and a net margin of 18.25%. The business’s quarterly revenue was down 6.9% on a year-over-year basis. During the same period in the prior year, the business posted $2.11 earnings per share. On average, equities analysts forecast that West Pharmaceutical Services, Inc. will post 6.4 earnings per share for the current fiscal year.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.